secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0001999371-25-008651
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix announces preclinical data for TNX-1700 in gastric cancer models published in Cancer Cell
--------------------------------------------------------------------------------

- mTNX-1700 plus anti-PD-1 increased survival and decreased metastases in gastric cancer animal models vs anti-PD-1 alone.
- Treatment associated with activation of CD8+ T cells and limiting neutrophil-mediated immune evasion.
- Human version TNX-1700 (hTFF2-HSA) is in preclinical development for gastric and colorectal cancers.
- Collaboration with Columbia University's Medical School; paper titled 'A CXCR4 Partial Agonist, Improves Immunotherapy...'.
- Data support further development of TNX-1700 to overcome resistance to anti-PD-1 immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125008651/0001999371-25-008651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125008651/tnxp-8k_070225.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-008651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer